OS Therapies Inc's Lock-Up Period Set To Expire on January 28th (NYSE:OSTX)

OS Therapies' (NYSE:OSTX - Get Free Report) lock-up period is set to end on Tuesday, January 28th. OS Therapies had issued 1,600,000 shares in its public offering on August 1st. The total size of the offering was $6,400,000 based on an initial share price of $4.00. After the expiration of OS Therapies' lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Maxim Group upped their price target on OS Therapies from $8.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday, January 16th. D. Boral Capital reiterated a "buy" rating and issued a $20.00 target price on shares of OS Therapies in a research note on Wednesday, January 15th.

OS Therapies Stock Up 5.8 %

Shares of OSTX stock traded up $0.17 during trading on Tuesday, hitting $3.12. The company's stock had a trading volume of 700,510 shares, compared to its average volume of 1,865,729. The business's fifty day moving average is $3.33. OS Therapies has a 52 week low of $1.58 and a 52 week high of $7.00.

Insider Buying and Selling at OS Therapies

In other news, major shareholder Shalom Auerbach sold 16,720 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $6.74, for a total transaction of $112,692.80. Following the completion of the sale, the insider now owns 2,531,211 shares in the company, valued at $17,060,362.14. This trade represents a 0.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Hedge Funds Weigh In On OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC purchased a new stake in shares of OS Therapies Inc (NYSE:OSTX - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 10,045 shares of the company's stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.